Scripps Genomic Medicine
Molecular Response, Scripps Genomic Medicine Partner
The R&D deal targets oncology and cardiovascular disease.
The study, which surveyed more than 2,000 people, found that the "results of a direct-to-consumer genomic risk test do not affect health-related behavior."
DTC Testing Survey Spotlights Acceptance and Concerns
A survey primarily using Scripps employees and Navigenics test offering shows that 50 percent of DTC genomics test takers have concerns, but over 80 percent want to know risks even of non-preventable diseases.
"We are concentrating on two initial areas — diabetes and aging research," Eric Topol, chief academic officer of Scripps Health, said. "Diabetes PGx work is of vital interest to Scripps, Sanofi, and the public."
Sanofi-aventis, Scripps Genomic Medicine Enter Personalized Medicine Alliance
Under terms of the alliance, a Sanofi-aventis Group subsidiary will fund each year up to three Discovery Innovation Grants intended to offer flexible financing for innovative research proposals from investigators at a division of Scripps Health.